uniQure Inc. has priced an upsized public offering of 4,945,055 ordinary shares at $45.50 each, aiming to raise approximately $225 million before expenses. The funds will support the company's development of transformative gene therapies for severe diseases, including hemophilia B, Huntington's disease, and epilepsy. The offering is expected to close around June 25, 2026, with an option for underwriters to buy additional shares. This capital raise underscores uniQure's commitment to advancing genomic medicine and expanding its treatment pipeline.
CEA Industries and YZi Labs have reached a cooperation agreement to strengthen governance at CEA Industries, which manages the world's largest corporate treasury of BNB. The agreement includes appointing three new board members with digital asset exp...
The TBG Dividend Focus ETF maintains a 'hold' rating due to its competitive fundamentals within its category. It offers a robust 12.75% projected EPS growth for next year and an estimated dividend yield of 3.59%, which surpasses its trailing yield of...
Bitcoin has been trading below $70,000 for about three weeks, with recent whale purchases totaling over $43 million failing to push the price above $65,000. Large investors, or whales, have dominated market activity since early June, but their buying...
HYLQ Strategy Corp. sold 54,461 HYPE tokens, generating $3.36 million at an average price of $61.76 each, realizing a 62% gain over its acquisition cost. This sale completes the monetization of its HYPE treasury position, totaling approximately 104,4...
Polymesh announced that its v8 upgrade will go live on Testnet starting June 24 and on Mainnet by July 22. This upgrade introduces significant features including self-registered decentralized identifiers (DIDs), easier asset transfers, expanded accou...
